Emerging drugs for the treatment of adult MOG-IgG-associated diseases

References

• Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89–102.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020 Oct 22; 6(1):85.
   PubMed Web of Science ®Google Scholar
• Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015Mar19;2(3):e89.
   PubMed Web of Science ®Google Scholar
• Carnero Contentti E, Lopez PA, Pettinicchi JP, et al. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM). Mult Scler Relat Disord. 2021 Jan 7;49:102742.
   PubMed Web of Science ®Google Scholar
• Von Büdingen HC, Hauser SL, Ouallet JC, et al. Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol. 2004 Aug;34(8):2072–2083.
   PubMed Web of Science ®Google Scholar
• O’Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007 Feb;13(2):211–217.
   PubMed Web of Science ®Google Scholar
• Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012 Jun;69(6):752–756.
   PubMedGoogle Scholar
• Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018 Apr 1;75(4):478–487.
   PubMed Web of Science ®Google Scholar
• Waters P, Fadda G, Woodhall M, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol. 2020Jan1;77(1):82–93.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018May22;90(21):e1858–e1869.
   PubMed Web of Science ®Google Scholar
• Á C-C, Ruiz A, D’Indy H, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017 Sep;264(9):1945–1955.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mohammad S, Tantsis E, et al., Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127–137.
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017 Dec 1;140(12):3128–3138.
   PubMedGoogle Scholar
• NOMADMUS, KidBioSEP, and OFSEP study groups, Cobo-Calvo A, Ruiz A, Rollot F, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2021 Jan;89(1):30–41.
   PubMed Web of Science ®Google Scholar
• Hennes EM, Baumann M, Schanda K, et al. BIOMARKER Study Group. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017Aug29;89(9):900–908.
   PubMed Web of Science ®Google Scholar
• OFSEP Group; REEM Group, Cobo-Calvo A, Sepúlveda M, d’Indy H, et al. Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol. 2019 Apr;266(4):806–815.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020 Jul 14;95(2):e111–e120.
   PubMed Web of Science ®Google Scholar
• Song H, Zhou H, Yang M, et al. Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China. J Ophthalmol. 2019 Apr 1;2019:4015075.
   PubMed Web of Science ®Google Scholar
• Lu Q, Luo J, Hao H, et al. Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. J Neurol. 2020 Sep 30. DOI: 10.1007/s00415-020-10236-4.
   Google Scholar
• Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019 Jul 2;16(1):134.
   PubMedGoogle Scholar
• Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3):e705.
   PubMed Web of Science ®Google Scholar
• Durozard P, Rico A, Boutiere C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 2020 Feb;87(2):256–266. .
   PubMed Web of Science ®Google Scholar
• Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020 Sep;44:102251.
   PubMed Web of Science ®Google Scholar
• Winklmeier S, Schlüter M, Spadaro M, et al. Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2019 Oct 14;6(6):625. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2019 Nov 15;7(1): Erratum in: Neurol Neuroimmunol Neuroinflamm. 2020 Dec 9;8(1): PMID: 31611268; PMCID: PMC6857907.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016Sep27;13(1):280.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352–1363.
   PubMed Web of Science ®Google Scholar
• Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020 Oct;45:102428.
   PubMed Web of Science ®Google Scholar